Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1473-1478

  Ogawa, Yasuhiro ^a   Murata, Yoriko ^a   Saibara, Toshiji ^a   Nishioka, Akihito ^a   Kariya, Shinji ^a   Yoshida, Shoji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Breast cancer; Computed tomography; CT; Fatty liver; NASH; Non alcoholic steatohepatitis; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; BEZAFIBRATE; TAMOXIFEN;

ADULT; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; FATTY LIVER; FEMALE; HUMAN; MIDDLE AGED; PROGNOSIS; TIME;

ADULT; ANTICARCINOGENIC AGENTS; BEZAFIBRATE; BREAST NEOPLASMS; DIABETES COMPLICATIONS; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; TAMOXIFEN; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 2142802643     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1473     Document Type: Article

References (32)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1-18, 71-85, 1992.
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998.
3. Fornander T, Rutqvist LE and Cedermark B: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117-120, 1989. (Pubitemid 19034031)
4. Ogawa Y, Murata Y, Nishioka A, Inomata T and Yoshida S: Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 351: 725, 1998. (Pubitemid 28105346)
5. Ogawa Y, Nishioka A, Inomata T, Tsuboi N, Hayase N, Fukumoto M, Yoshida S, Tochika N, Tanaka Y and Kumon M: Conservation treatment intensified with tamoxifen and CAF chemotherapy for subareolar breast cancers. Oncol Rep 5: 1337-1341, 1998. (Pubitemid 28474072)
6. Ogawa Y, Nishioka A, Inomata T, Yokota N, Sasaki T, Terashima M, Yoshida S, Tanaka Y and Tochika N: Conservation treatment intensified with tamoxifen and CAF chemotherapy without axillary dissection for early breast cancer patients with clinically-negative axillary nodes. Oncol Rep 6: 801-805, 1999.
7. Ogawa Y, Nishioka A, Inomata T, Ohnishi T, Kariya S, Terashima M, Yoshida S, Tochika N, Tanaka Y and Kumon M: Coservation treatment intensified with an anti-estrogen agent and CAF chemotherapy for stage I and II breast cancer. Oncol Rep 7: 479-484, 2000.
8. Terashima M, Ogawa Y, Kariya S, Inomata T, Nishioka A, Shimizu K, Yamanishi T, Tanaka Y, Tochika N and Yoshida S: Breast-conservation treatment for patients with ductal carcinoma in situ. Oncol Rep 7: 1247-1252, 2000.
9. Ogawa Y, Kobayashi T, Nishioka A, Kariya S, Garcia del Saz E, Seguchi H and Yoshida S: Sudden termination of G-CSF injection leads to apoptosis of a large proportion of increased granulocytes. Oncol Rep 8: 1027-1029, 2001. (Pubitemid 33758163)
10. Hamada N, Ogawa Y, Nishioka A, Kariya S, Terashima M, Yoshida S, Tanaka Y and Inomata T: An elderly patient with DCIS of the breast effectively treated with toremifene alone. Oncol Rep 9: 475-478, 2002.
11. Hamada N, Ogawa Y, Nishioka A, Kariya S, Terashima M, Yoshida S, Tochika N, Tanaka Y, Kumon M and Inomata T: Breast-conservation treatment for bilateral breast cancer in five Japanese women. Oncol Rep 9: 469-474, 2002.
12. Kariya S, Ogawa Y, Nishioka A and Yoshida S: Docetaxel-cisplatin combined chemotherapy in Japanese patients with anthracycline-pretreated advanced breast cancer. Oncol Rep 9: 1345-1349, 2002.
13. Kato K, Takayama T, Katada N, Nishimura D, Shibata T, Kato K and Takechi M: Evaluation of computed tomography in the diagnosis of liver diseases. Acta Hepatol Jpn 21: 1340-1351, 1980.
14. Hata Y, Ogawa Y, Nishioka A, Inomata T and Yoshida S: Thin section CT in the prone position for detection of axillary lymph node metastases in breast cancer. Oncol Rep 5: 1403-1406, 1998. (Pubitemid 28474084)
15. Tsuboi N, Ogawa Y, Inomata T, Yoshida D, Yoshida S, Moriki T and Kumon M: Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III - Pathologic correlation. Oncol Rep 6: 727-732, 1999.
16. Nishioka A, Ogawa Y, Hamada N, Terashima M, Inomata T and Yoshida S: Analysis of radiation pneumonitis and radiation-induced lung fibrosis in breast cancer patients after breast-conservation treatment. Oncol Rep 6: 513-517, 1999.
17. Takeuchi N, Fukumoto M, Nishioka A, Akagi N, Murata Y, Takeuchi S, Ogawa Y and Yoshida S: Scintigraphic prediction of response to chemotherapy in patients with breast cancer: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. Int J Oncol 20: 53-58, 2002.
18. Kubota K, Hisa N, Ogawa Y and Yoshida S: Evaluation of tissue harmonic imaging for breast tumors and axillary lymph nodes. Oncol Rep 9: 1335-1338, 2002.
19. Ogawa Y, Nishioka A, Nishigawa T, Kubota K, Kariya S, Yoshida S, Tanaka Y, Moriki T and Tochika N: Thin-section CT evaluation and pathologic correlation of therapeutic effect of neoadjuvant chemotherapy for axillary lymph nodes of clinically node-positive breast cancer patients. Oncol Rep 10: 985-989, 2003.
20. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR and MacSween RNM: Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 353: 36-37, 1999. (Pubitemid 29037704)
21. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S and Yoshida S: Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7: 1299-1304, 2000.
22. Hamada N, Ogawa Y, Saibara T, Murata Y, Kariya S, Nishioka A, Terashima M, Inomata T and Yoshida S: Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 17: 1119-1123, 2000.
23. Nemoto Y, Saibara T, Ogawa Y, Zhang T, Xu N, Ono M, Akisawa N, Iwasaki S, Maeda T and Onishi S: Tamoxifen-induced non-alcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Internal Med 41: 345-350 2002. (Pubitemid 34746176)
24. Murata Y, Ogawa Y, Saibara T, Nishioka A, Takeuchi N, Kariya S, Onishi S and Yoshida S: Tamoxifen-induced nonalcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep 10:97-100, 2003.
25. Saibara T, Onishi S, Ogawa Y, Yoshida S and Enzan H: Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis Lancet 353: 1802, 1999.
26. Nemoto Y, Toda K, Ono M, Adachi K, Saibara T, Onishi S, Enzan H, Okada T and Shizuta Y: Altered constitutive expression of fatty acid-metabolizing enzymes in aromatase-deficient (ArKO) mice. J Clin Invest 105: 1819-1825, 2000. (Pubitemid 30421763)
27. Vamecq J and Latruffe N: Medical significance of peroxisome proliferator-activated receptors. Lancet 354: 141-148, 1999. (Pubitemid 29313157)
28. Kusarna H, Nishiyama M, Matsubara Y and Ikeda S: Pharmacological investigation of bezafibrate, a hypolipidemic agent (2). Mechanism of the hypolipidemic action of bezafibrate in rats Jpn J Pharmacol 92: 181-191, 1988.
29. Burt AD and MacSween RNM: Pathology of alcoholic liver disease. In: Oxford Textbook of Clinical Hepatology. Bircher J, Benhamou J-P, Mclntyre N, et al (eds). Oxford University Press, Oxford, pp1179-1185, 1999.
30. Saibara T, Ogawa Y and Onishi S: Tamoxifen in early breast cancer. Lancet 352: 404, 1998.
31. Saibara T, Onishi S, Ogawa Y, Yoshida S and Enzan H: Nonalcoholic steatohepatitis. Lancet 354: 1229-1300, 1999.
32. Wakatsuki A, Ogawa Y, Saibara T, Okatani Y and Fukaya T: Size and oxidative susceptibility of low-density lipoprotein particles in breast cancer patients with tamoxifen-induced fatty liver. J Clin Endocrinol Metab 87: 3676-3681, 2002. (Pubitemid 34879512)